

**IN THE CLAIMS**

Please cancel claims 62, 63, 65, and 67, without prejudice. Please amend claims as shown below. The following listing of claims replaces all prior listings.

1-15. (cancelled)

16. (currently amended) A compound, ~~selected from the group consisting of~~ comprising a phosphonate ester formed by a covalent linking of an antiviral compound selected from the group consisting of cidofovir, adefovir, cyclic cidofovir and tenofovir, ~~covalently linked to an alcohol selected from the group consisting of~~ an alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol, or its a pharmaceutically acceptable salt thereof.

17. (previously presented) The compound of claim 16, wherein the antiviral compound is cidofovir.

18. (currently amended) The compound of claim 17, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylpropanediol.

19. (currently amended) The compound of claim 17, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylethanediol.

20. (currently amended) The compound of claim 17, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkoxyalkanol.

21. (currently amended) The compound of claim 17 ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylglycerol.

22. (currently amended) The compound of claim 17, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an 1-S-alkylthioglycerol.

23. (previously presented) The compound of claim 16, wherein the antiviral compound is adefovir.
24. (currently amended) The compound of claim 23, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylpropanediol.
25. (currently amended) The compound of claim 23, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylethanediol.
26. (currently amended) The compound of claim 23, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkoxyalkanol.
27. (currently amended) The compound of claim 23, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylglycerol.
28. (currently amended) The compound of claim 23, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an 1-S-alkylthioglycerol.
29. (previously presented) The compound of claim 16, wherein the antiviral compound is cyclic cidofovir.
30. (currently amended) The compound of claim 29 ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylpropanediol.
31. (currently amended) The compound of claim 29, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylethanediol.
32. (currently amended) The compound of claim 29, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkoxyalkanol.


33. (currently amended) The compound of claim 29, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylglycerol.
34. (currently amended) The compound of claim 29, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an 1-S-alkylthioglycerol.
35. (previously presented) The compound of claim 16, wherein the antiviral compound is tenofovir.
36. (currently amended) The compound of claim 35, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylpropanediol.
37. (currently amended) The compound of claim 35, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylethenediol.
38. (currently amended) The compound of claim 35, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkoxyalkanol.
39. (currently amended) The compound of claim 35, ~~which~~ wherein the alcohol is covalently ~~linked to~~ an alkylglycerol.
40. (currently amended) The compound of claim 35 ~~which~~ wherein the alcohol is covalently ~~linked to~~ an 1-S-alkylthioglycerol.
41. (currently amended) The compound of claim 16, wherein the phosphonate ester is formed by ~~linked~~ linking the antiviral compound to the alcohol through the 3-position of the ~~molecule~~ alkylglycerol, alkylpropanediol, or 1-S-alkylthioglycerol.
42. (currently amended) The compound of claim 16, wherein the phosphonate moiety in the ester is a phosphonate or a methylene phosphonate.

43. (currently amended) The compound of claim 16, wherein the ~~phosphonate of an antiviral compound is covalently linked to~~ alcohol is an alkylpropanediol.
44. (currently amended) The compound of claim ~~43~~ 41, wherein the antiviral compound is cidofovir.
45. (previously presented) The compound of claim 43, wherein the alkylpropanediol is 1-O-hexadecylpropanediol or 1-octadecylpropanediol.
46. (previously presented) The compound of claim 43, wherein the alkylpropanediol is 1-O-hexadecylpropanediol or 1-O-octadecylpropanediol and the antiviral compound is cyclic cidofovir.
47. (previously presented) The compound of claim 43, wherein the alkylpropanediol is 1-O-octadecylpropanediol.
48. (currently amended) The compound of claim 16, wherein the ~~phosphonate of an antiviral compound is covalently linked to~~ the alcohol is an alkylethanol.
49. (currently amended) The compound of claim ~~48~~ 45, wherein the antiviral compound is cidofovir.
50. (currently amended) The compound of claim ~~49~~ 48, wherein the alkylethanol is 1-O-octadecylethanol.
51. (currently amended) The compound of claim 16, wherein the ~~phosphonate of an antiviral compound is covalently linked to~~ alcohol is an alkylglycerol.
52. (previously presented) The compound of claim 51, wherein the antiviral compound is cidofovir.

53. (currently amended) The compound of claim ~~52~~ 51, wherein the alkylglycerol is a 1-O-alkylglycerol.
54. (currently amended) The compound of claim ~~52~~ 51, wherein the alkylglycerol is a 3-O-alkylglycerol.
55. (currently amended) The compound of claim ~~51~~ 53, wherein the antiviral compound is cyclic cidofovir.
56. (currently amended) The compound of claim ~~55~~ 54, wherein the ~~alkylglycerol is a 1-O-alkylglycerol~~ antiviral compound is cyclic cidofovir.
57. (currently amended) The compound of claim ~~55~~ 54, wherein the ~~alkylglycerol is a 3-O-alkylglycerol~~ the antiviral compound is cidofovir.
58. (currently amended) The compound of claim ~~51~~ 53, wherein the antiviral compound is adefovir.
59. (currently amended) The compound of claim ~~58~~ 54, wherein the ~~alkylglycerol is a 1-O-alkylglycerol~~ antiviral compound is adefovir.
60. (currently amended) The compound of claim ~~58~~ 53, wherein the ~~alkylglycerol is a 3-O-alkylglycerol~~ antiviral compound is tenofovir.
61. (currently amended) The compound of claim ~~51~~ 54, wherein the antiviral compound is tenofovir.
62. (canceled).
63. (canceled).

64. (currently amended) The compound of claim 16, wherein ~~the phosphonate of an antiviral compound is covalently linked to~~ the alcohol is a 1-S-alkylthioglycerol.
65. (canceled).
66. (currently amended) The compound of claim 16, wherein ~~the phosphonate of an antiviral compound is covalently linked to~~ the alcohol is an alkoxyalkanol.
67. (canceled).
68. (previously presented) The compound of claim 66, wherein the alkoxyalkanol is a 1-O-alkylpropane-3-ol.
69. (previously presented) The compound of claim 68, wherein the antiviral compound is cidofovir.
70. (previously presented) The compound of claim 68, wherein the antiviral compound is cyclic cidofovir.
71. (previously presented) The compound of claim 68, wherein the antiviral compound is tenofovir.
72. (previously presented) The compound of claim 68, wherein the antiviral compound is adefovir.
73. (previously presented) A method for the treatment of a viral disease selected from human immunodeficiency virus, influenza, herpes simplex virus, human herpes virus, cytomegalovirus, hepatitis B and C virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus comprising administering an effective amount of a compound of claim 16 optionally in a pharmaceutically acceptable carrier.

74. (currently amended) The method of claim 73 wherein the virus is an orthopox virus is selected from variola major and minor, vaccinia, smallpox, cowpox, camelpox and monkeypox.
75. (currently amended) The method of claim 73, wherein the virus is ~~HIV~~ human immunodeficiency virus.
76. (currently amended) The methods of claim 73, wherein the virus is influenza.
77. (previously presented) The method of claim 73, wherein the virus is herpes.
78. (previously presented) The method of claim 73, wherein the virus is cytomegalovirus.
79. (previously presented) The method of claim 73, wherein the virus is hepatitis B.
80. (previously presented) The method of claim 73, wherein the virus is hepatitis C.
81. (previously presented) The method of claim 73, wherein the virus is Epstein-Barr virus.
82. (currently amended) The method of claim ~~58~~ 73, wherein the virus is varicella zoster virus.
83. (previously presented) The method of claim 73, wherein the virus is papilloma.
84. (currently amended) The ~~antiviral-phosphonate~~ compound of claim 16, having the following structure or ~~its~~ a pharmaceutically acceptable salt thereof:

Nc1ccnc(=O)n1CC[C@H](O)COP(=O)(O)OCCOC(CCO)CCCCCCCCCCCCCCC

89. (previously presented) 1-O-hexadecylpropanediol-3-cyclic cidofovir.



90. (previously presented) 1-O-octadecylpropanediol-3-cyclic cidofovir.
91. (previously presented) 1-O-octadecylethanol-2-cyclic cidofovir.
92. (previously presented) 1-O-hexadecylpropanediol-3-adeфовir.
93. (previously presented) 1-O-octadecyl-sn-glycero-3-adeфовir.
94. (currently amended) A pharmaceutical composition comprising an effective amount of an ~~antiviral phosphonate~~ compound of any one of claims 16 ~~or~~ and 84-93 in combination with a pharmaceutically acceptable carrier.